Biotech RadarJobs updated

COMPANY

Enanta Pharmaceuticals

enanta.com ↗ · New England

Clinical Phase 2

Keywords: immunology viral infections RSV Infection Respiratory Syncytial Virus COVID-19 NASH - Nonalcoholic Steatohepatitis Non-Alcoholic Steatohepatitis Chronic HBV Infection NASH Hepatitis C RSV Chronic Inducible Urticaria Chronic Spontaneous Urticaria QTc Interval Drug Drug Interaction Respiratory Syncytial Virus Infections SARS CoV 2 Infection Chronic Hepatitis B Virus Infection NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis Hepatitis B Primary Biliary Cholangitis Presumptive NAFLD Hepatitis C Virus SSTI MRSA Skin and Soft Tissue Infections Methicillin-resistant Staphylococcus Aureus Community Acquired Pneumonia EDP-938 EDP-323 EDP-235 EDP-514 EDP-305 EDP239 EDP-788 EDP-322 zelicapavir EDP-978

Profile checked Oct 10, 2026

45Trials (company is sponsor)3NIH grants

Timeline

  1. Trial start 2: A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus source ↗
  2. Trial start Phase 1: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults source ↗
  3. Trial start Phase 1: A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants source ↗
  4. Trial start Phase 1: A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. source ↗
  5. Trial start Phase 1: A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults source ↗
  6. Trial start 2: A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model source ↗
  7. Trial start Phase 2: A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. source ↗
  8. Trial start Phase 2: A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 source ↗
  9. Trial start Phase 1: Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects source ↗
  10. Trial start Phase 1: Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects. source ↗
  11. Trial start Phase 1: A Study of EDP-323 in Healthy Subjects source ↗
  12. Trial start Phase 2: A Study to Evaluate EDP 938 Regimens in Children With RSV source ↗
  13. Trial start Phase 1: A Study of EDP-235 in Healthy Subjects source ↗
  14. Trial start Phase 1: A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. source ↗
  15. Trial start Phase 2: Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract source ↗
  16. Trial start Phase 1: Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects source ↗
  17. Trial start Phase 1: Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects source ↗
  18. Trial start Phase 1: Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects source ↗
  19. Trial start Phase 1: A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment source ↗
  20. Trial start Phase 1: A Study of EDP-297 in Healthy Subjects source ↗
  21. Trial start Phase 1: Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects source ↗
  22. Trial start Phase 2: A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH source ↗
  23. Trial start Phase 2: A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects source ↗
  24. Trial start Phase 1: A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2) source ↗
  25. Trial start Phase 1: Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects source ↗

Showing 25 of 44 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 45

RecordTitlePhaseStatusStartPrimary completion
NCT05568706A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.Phase 2CompletedNov 29, 2022Jun 23, 2025 (actual)
NCT07482657A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus2RecruitingJul 9, 20262026-12 (estimated)
NCT07540910A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy AdultsPhase 1RecruitingApr 1, 20262026-11 (estimated)
NCT06170242A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model2CompletedNov 20, 2023Jun 17, 2024 (actual)
NCT04816721A Study to Evaluate EDP 938 Regimens in Children With RSVPhase 2CompletedApr 26, 2022Aug 19, 2024 (actual)
NCT06601192A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy AdultsPhase 1CompletedJul 15, 2024Feb 2, 2025 (actual)
NCT06917508A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy ParticipantsPhase 1CompletedMar 13, 2025Jun 6, 2025 (actual)
NCT06847464A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.Phase 1CompletedJan 27, 2025May 24, 2025 (actual)
NCT04633187Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory TractPhase 2TerminatedJul 7, 2021May 31, 2023 (actual)
NCT05616728A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19Phase 2CompletedNov 10, 2022Feb 8, 2023 (actual)
NCT04196101A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult SubjectsPhase 2CompletedJan 22, 2020Jan 4, 2022 (actual)
NCT05587478A Study of EDP-323 in Healthy SubjectsPhase 1CompletedSep 29, 2022Mar 29, 2023 (actual)
NCT04378010A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASHPhase 2TerminatedJan 27, 2020Oct 4, 2021 (actual)
NCT05594615Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy SubjectsPhase 1CompletedOct 6, 2022Nov 4, 2022 (actual)
NCT05594602Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.Phase 1CompletedOct 6, 2022Dec 14, 2022 (actual)
NCT05246878A Study of EDP-235 in Healthy SubjectsPhase 1CompletedJan 28, 2022Jul 20, 2022 (actual)
NCT03691623A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model2CompletedOct 15, 2018Sep 30, 2019 (actual)
NCT04927793Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male SubjectsPhase 1CompletedMay 28, 2021Jul 4, 2021 (actual)
NCT04971512A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.Phase 1TerminatedAug 2, 2021Dec 20, 2021 (actual)
NCT04008004A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)Phase 1CompletedJun 26, 2019Jul 14, 2021 (actual)
NCT04470388A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on TreatmentPhase 1CompletedSep 9, 2020Aug 30, 2021 (actual)
NCT04559126A Study of EDP-297 in Healthy SubjectsPhase 1CompletedSep 8, 2020Jun 21, 2021 (actual)
NCT04498741Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy SubjectsPhase 1CompletedJul 8, 2020May 27, 2021 (actual)
NCT03421431A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic SteatohepatitisPhase 2CompletedApr 25, 2018Jun 14, 2019 (actual)
NCT04783753Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy SubjectsPhase 1CompletedNov 5, 2020Jun 28, 2021 (actual)
NCT03394924A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary CholangitisPhase 2CompletedDec 27, 2017Dec 19, 2019 (actual)
NCT04871724Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy SubjectsPhase 1CompletedMar 12, 2021Mar 30, 2021 (actual)
NCT03783897A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female SubjectsPhase 1CompletedNov 27, 2018Jun 4, 2019 (actual)
NCT03755778Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy SubjectsPhase 1CompletedNov 29, 2018Jan 21, 2019 (actual)
NCT03750383Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult SubjectsPhase 1CompletedNov 2, 2018Nov 17, 2018 (actual)
NCT03610945Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy VolunteersPhase 1CompletedJul 19, 2018Aug 15, 2018 (actual)
NCT03748628Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male SubjectsPhase 1CompletedOct 5, 2018Oct 13, 2018 (actual)
NCT03384823A Study of EDP-938 in Healthy SubjectsPhase 1CompletedDec 7, 2017Jul 3, 2018 (actual)
NCT03213145Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy VolunteersPhase 1CompletedJul 11, 2017Aug 10, 2017 (actual)
NCT03207425A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy VolunteersPhase 1CompletedJun 14, 2017Sep 16, 2017 (actual)
NCT03187496Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.Phase 1CompletedMay 11, 2017Jun 1, 2017 (actual)
NCT02918929A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLDPhase 1Completed2016-092017-06 (actual)
NCT02652377EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C PatientsPhase 1CompletedJan 10, 2016Dec 27, 2016 (actual)
NCT01856426Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C SubjectsPhase 1Completed2013-062014-11 (actual)
NCT02255968Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788Phase 1Terminated2014-082014-10 (actual)
NCT01999725Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788Phase 1Completed2014-012014-09 (actual)
NCT02173574Two-way Interaction Between Alisporivir and EDP239Phase 1Completed2014-082014-11 (actual)
NCT00990145Multiple Ascending-Dose Study of EDP 322 in Healthy Adult VolunteersPhase 1Completed2008-112009-03 (actual)
NCT00989872Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy VolunteersPhase 1CompletedNot listedNot listed
NCT00270517Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired PneumoniaPhase 2Unknown status (ClinicalTrials.gov)2005-12Not listed

NIH awards 3

Annual award amounts. Total $23.6M.

Feedback